Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;8(2):259-267.
doi: 10.1007/s13555-018-0233-6. Epub 2018 Mar 24.

Drug Treatment for Androgenetic Alopecia: First Italian Questionnaire Survey on What Dermatologists Think about Finasteride

Elisabetta Sorbellini  1 , Daniela Pinto  1 , Barbara Marzani  1 , Fabio Rinaldi  2
Affiliations

Drug Treatment for Androgenetic Alopecia: First Italian Questionnaire Survey on What Dermatologists Think about Finasteride

Elisabetta Sorbellini et al. Dermatol Ther (Heidelb). 2018 Jun.

Abstract

Introduction: Treatment with finasteride 1 mg/day represents the therapy of choice for androgenetic alopecia (AGA). We investigated how Italian dermatologists approach use of finasteride for treatment of AGA and common side effects reported by patients.

Methods: A tablet-based survey was conducted from February 2017 to January 2018 in Italy to investigating use of 1 mg/day finasteride in the treatment of AGA. Approximately 1153 Italian dermatologists were surveyed about prescription frequency, therapy duration, treatment practices, and side effects eventually reported.

Results: Dermatologists considered treatment with 1 mg/day finasteride to be the most efficacious treatment for AGA, as reflecting by its long-term (5 years) prescription. Data on sexual side effects from our survey are in line with previous scientific evidence, especially regarding loss of libido, erectile dysfunction, and problems with ejaculation, but also in the psychological sphere and regarding physical impairments such as myalgia and loss of muscle tone.

Conclusions: This is the first preliminary observational study on how Italian dermatologists approach use of finasteride to treat AGA. Although side effects have been reported, especially in the sexual sphere, lack of alternative treatments with the same efficacy leads dermatologists to prescribe 1 mg/day finasteride with a tendency to prolong therapy in the long term.

Funding: Giuliani S.p.A.

Keywords: Androgenetic alopecia; Finasteride; Male pattern baldness; Physical impairment; Psychological-sphere side effects; Sexual side effects.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Survey report on use of 1 mg/day finasteride as main oral treatment in patients affected by AGA
Fig. 2
Fig. 2
Survey report on a percentage of 1 mg finasteride prescription in patients affected by AGA and b explanations behind lack of prescription (“I’m not confident about efficacy,” “I’m thinking about side effects,” “I think the cost of therapy is too high”)
Fig. 3
Fig. 3
Survey report about how long dermatologists advise AGA patients to take 1 mg finasteride (“6 months,” “1 year,” “2 years,” “5 years”)
Fig. 4
Fig. 4
Survey results regarding reported sexual side effects: a loss of libido, b erectile dysfunction/impotence, c decreased ejaculation, d scrotal pain, e decreased penis sensitivity, and f decreased penis temperature
Fig. 5
Fig. 5
Survey results regarding side effects reported in the psychological sphere: a diminished quality of life, b lack of concentration, and c depression
Fig. 6
Fig. 6
Survey results regarding physical impairments: a myalgia and b loss of muscle tone
See this image and copyright information in PMC

References

    1. Tosti A, Piraccini BM. Androgenetic alopecia. Int J Dermatol. 1999;38(Suppl 1):1–7. doi: 10.1046/j.1365-4362.1999.00002.x. - DOI - PubMed
    1. Paus R, Olsen EA, Messenger AG. Hair growth disorders. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, et al., editors. Fitzpatrick’s dermatology in general medicine. 7th ed. New York: McGraw-Hill; 2007. p. 753–77.
    1. Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: an update. Indian J Dermatol Venereol Leprol. 2013;79(5):613–625. doi: 10.4103/0378-6323.116730. - DOI - PubMed
    1. Piraccini BM, Alessandrini A. Androgenetic alopecia. G Ital Dermatol Venereol. 2014;149(1):15–24. - PubMed
    1. Hagenaars SP, Hill WD, Harris SE, et al. Genetic prediction of male pattern baldness. Noethen MM, ed. PLoS Genet. 2017;13(2):e1006594. doi: 10.1371/journal.pgen.1006594. - DOI - PMC - PubMed

LinkOut - more resources